Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).

  • 0 views
  • 07 Jul, 2021
  • 78 locations
Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy

membranous nephropathy (MN) who are at high risk of disease progression defined on the basis of antibody anti-PLA2R titre and proteinuria.

rituximab
lnp023
proteinuria
diuretics
kidney biopsy
  • 22 views
  • 14 Jul, 2021
  • 31 locations
Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)

This is an open-label, multicentre study to characterize the safety and efficacy of the human anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous

cyclosporine
mycophenolate
mor202
immunosuppression
immunosuppressive agents
  • 23 views
  • 31 Mar, 2021
  • 49 locations
Efficacy Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE)

-PLA2R antibody-positive membranous nephropathy indicated for immunosuppressive therapy

remission
fibrosis
glomerular filtration rate
nephropathy
proteinuria
  • 0 views
  • 12 Jun, 2021
  • 16 locations
Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)

The trial is a random, open, control and monocentric trial. Mainly to assess the urine protein remission rate of tacrolimus (TAC) monotherapy for idiopathic membranous nephropathy (IMN

remission
tacrolimus
prednisone
nephrotic syndrome
kidney biopsy
  • 39 views
  • 22 Jan, 2021
  • 1 location
Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy

This random, open, control and multicenter clinical trial mainly aims to assess the urine protein remission rate of tacrolimus (TAC) monotherapy for idiopathic membranous nephropathy (IMN

remission
tacrolimus
prednisone
nephrotic syndrome
kidney biopsy
  • 7 views
  • 22 Jan, 2021
  • 1 location
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Background Membranous nephropathy is associated with damage to the walls of the glomeruli, the small blood vessels in the kidneys that filter waste products from

cyclosporine
nephropathy
angiotensin ii receptor antagonists
rituximab
immunosuppressive agents
  • 236 views
  • 28 Jul, 2021
  • 2 locations
Personalized Medicine for Membranous Nephropathy

Membranous Nephropathy with nephrotic syndrome and anti-PLA2R1 (phospholipase A2 receptor 1) antibodies GEMRITUX protocol: 6 months of symptomatic antihypertensive and

protein creatinine ratio
remission
antihypertensive
rituximab
immunosuppressive agents
  • 0 views
  • 24 Jan, 2021
  • 24 locations
Belimumab With Rituximab for Primary Membranous Nephropathy

participants with PM. Background Primary membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults. MN affects individuals of all ages

remission
mammogram
nephropathy
arthritis
monoclonal antibodies
  • 206 views
  • 28 Jan, 2021
  • 10 locations
A Study of the Safety Tolerability Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN

membranous nephropathy (iMN) who are on ACE inhibitor or angiotensin II receptor blocker treatment.

protein creatinine ratio
angiotensin
kidney biopsy
nephrotic syndrome
ace inhibitor
  • 0 views
  • 25 Jan, 2021
  • 1 location